ECTRIMS 2021 | sNfL identifies patients at higher risk of future disease activity beyond NEDA-3 status

Jens Kuhle, MD, PhD, University Hospital and University of Basel, Basel, Switzerland, discusses the added value of assessing serum neurofilament light chain (sNfL) levels in combination with no evidence of disease activity-3 (NEDA-3) status in patients with multiple sclerosis (MS). A study of over 155 patients with early relapsing-remitting MS was conducted, where disease activity was investigated in subgroups defined by NEDA-3 status and high or low sNfL. The study showed that higher NfL levels significantly increased the risk of disease activity in the next year in NEDA-3 patients, compared to patients with low sNfL. These data suggest the sNfL can be a valuable marker to identify patients at risk of future disease activity beyond their NEDA-3 status. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.